Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
The FDA granted accelerated approval to sacituzumab govitecan in April based on results seen in patients with triple-negative breast cancer. However, there is still more to learn about resistance to the antibody drug conjugate and what leads to treatment failure, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Transcript
What clinical activity of sacituzumab govitecan led to its FDA accelerated approval status earlier this year?
As a single agent, a response rate of 33% was noted with sacituzumab govitecanin patients who had received at least 2 prior lines of therapy for metastatic triple-negative breast cancer. And in this setting, standard chemotherapy would be associated with a response rate of 5% to 10%. So it was more than double as compared to what you would see with standard chemotherapy. And that's why the FDA granted accelerated approval to this agent.
What causes immuno-oncology treatment failure and how are clinicians alerted to this?
That's an area of ongoing research. We don't really understand the mechanisms governing resistance to sacituzumab govitecan, and that's something that we are interested in understanding so that we can build additional therapies and further improve outcomes of patients with metastatic disease.
In terms of what physicians should look out for, standard signs of disease progression. So if someone is having more pain, more symptoms, there's concern for disease progression, [and] then scans should be obtained. Any therapy that's effective should be continued. But if a therapy has stopped working, you should not waste time by continuing an ineffective therapy.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Mammography Use Linked to Social Determinants, Revealing Need to Bridge Gaps With Community Support
April 9th 2024While mammograms are crucial for early detection of breast cancer and can save lives, social determinants of health and health-related social needs create barriers to access, especially for those with financial hardship, lack of transportation, or social isolation.
Read More